Market Research Logo

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016’, provides in depth analysis on Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted pipeline therapeutics.

The report provides comprehensive information on the Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2)
    • The report reviews Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics and enlists all their major and minor projects
    • The report assesses Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2)
    • Identify the use of drugs for target identification and drug repurposing
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) development landscape
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


    Introduction
    Global Markets Direct Report Coverage
    Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) Overview
    Therapeutics Development
    Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Products under Development by Stage of Development
    Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Products under Development by Therapy Area
    Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Products under Development by Indication
    Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Products Glance
    Late Stage Products
    Early Stage Products
    Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Products under Development by Companies
    Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Products under Development by Universities/Institutes
    Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Therapeutics Assessment
    Assessment by Monotherapy/Combination Products
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Companies Involved in Therapeutics Development
    Catalyst Biosciences, Inc.
    H. Lundbeck A/S
    NeuroDerm Ltd.
    Saniona AB
    Suven Life Sciences Ltd.
    Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Drug Profiles
    (nicotine + opipramol hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NS-9283 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for Obesity and Metabolic Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for Pain - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize nAChR Alpha-4 Beta-2 for Neurological and Psychiatric disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SUVN-911 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TC-8831 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    varenicline tartrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Dormant Projects
    Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Discontinued Products
    Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Featured News & Press Releases
    May 23, 2016: CHAMPIX (Varenicline) European Union Label Updated To Include New Safety And Efficacy Data From The EAGLES Clinical Trial Following Endorsement From CHMP
    Apr 22, 2016: CHANTIX/CHAMPIX (Varenicline) Results From The Largest Global Clinical Trial Of Smoking Cessation Medicines Published In The Lancet
    Sep 04, 2015: Quit-smoking drug safer than thought
    Mar 09, 2015: FDA updates label for stop smoking drug Chantix
    Mar 09, 2015: Suven Life secures One (1) Product Patent each in Eurasia and Israel
    Oct 06, 2014: US District Court Dismisses All Claims Related To Pfizer’s Chantix
    Jan 21, 2014: CHANTIX/CHAMPIX (varenicline) Demonstrates Smoking-Cessation Efficacy In Smokers Unwilling or Unable To Quit Abruptly
    Jun 03, 2013: NIH Researchers Find Varenicline As Promising Treatment For Alcohol Dependence
    Feb 28, 2013: Pfizer Pays $273m For Settlement Of Lawsuits Related To Anti-smoking Drug Chantix
    Jan 24, 2013: Pfizer's Chantix Demonstrates Efficacy In Smokers Who Previously Attempted To Quit Smoking With Chantix
    Dec 12, 2012: FDA Provides Updated Information Of Safety Review On Risk Of Cardiovascular Adverse Events Associated With Pfizer's Chantix
    Oct 16, 2012: Pfizer Completes Efficacy And Safety Study Of Smoking Cessation Drug Chantix
    Jan 19, 2012: Health Canada Completes Review Of Pfizer's Smoking-Cessation Drug, Champix
    Jul 21, 2011: European Medicines Agency Confirms Positive Benefit-Risk Balance For Champix
    Jul 21, 2011: European Medicines Agency Confirms Positive Benefit-Risk Balance For Pfizer's Champix
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for, H2 2016
    Number of Products under Development by Therapy Area, H2 2016
    Number of Products under Development by Indication, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Number of Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Assessment by Monotherapy/Combination Products, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Pipeline by Catalyst Biosciences, Inc., H2 2016
    Pipeline by H. Lundbeck A/S, H2 2016
    Pipeline by NeuroDerm Ltd., H2 2016
    Pipeline by Saniona AB, H2 2016
    Pipeline by Suven Life Sciences Ltd., H2 2016
    Dormant Projects, H2 2016
    Dormant Projects (Contd..1), H2 2016
    Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for, H2 2016
    Number of Products under Development by Therapy Area, H2 2016
    Number of Products under Development by Top 10 Indication, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy/Combination Products, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report